Weiss, Jared <br/><br/>
Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.  [electronic resource] 

 -  Oral oncology  09 2018 
 - 46-51 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0593 
<br/><br/><label>Standard No.: </label>10.1016/j.oraloncology.2018.06.028  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Albumins--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carboplatin--administration & dosage<br/>Cetuximab--administration & dosage<br/>Chemoradiotherapy--adverse effects<br/>Cisplatin--administration & dosage<br/>Combined Modality Therapy<br/>Drug Eruptions--etiology<br/>Female<br/>Head and Neck Neoplasms--drug therapy<br/>Humans<br/>Induction Chemotherapy<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy--adverse effects<br/>Neoplasm Staging<br/>Neutropenia--chemically induced<br/>Paclitaxel--administration & dosage<br/>Progression-Free Survival<br/>Radiotherapy, Intensity-Modulated--adverse effects<br/>Squamous Cell Carcinoma of Head and Neck--drug therapy<br/>Treatment Outcome